Table.

Change in Energy and Exertional Fatigue Outcome (EnergyFatigEx) for Placebo vs Statin Groups^a

	Placebo, Mean (SD)	Statin		Simvastatin		Pravastatin
		Mean (SD)	P Valueb	Mean (SD)	P Value	Mean (SD)	P Valueb
Allc	−0.06 (0.71)	−0.21 (0.87)	.005	−0.25 (0.87)	.002	−0.17 (0.86)	.06
Women	−0.08 (0.72)	−0.39 (1.14)	.01	−0.47 (1.20)	.004	−0.31 (1.08)	.07

^aEnergyFatigEx score range, −4 to +4. A 0.4-drop (observed for women receiving simvastatin vs placebo) would arise if 4 in 10 treated women cited worsening in either energy or exertional fatigue; 2 in 10 cited worsening on both measures or rated themselves “much worse” on 1 measure; 1 in 10 rated themselves “much worse” on both measures; or combinations of these conditions, with the fractions of subjects for which each statement holds, summing to 1.

Sample sizes: placebo (n = 342), statin (n = 670), simvastatin (n = 332), and pravastatin (n = 338). Sample sizes for women: placebo (n = 110), statin (n = 213), simvastatin (n = 105), pravastatin (n = 108). Mean (SD) baseline EnergyFatigEx values (imputing missing values) (scale, 0 to 20): placebo, 16.8 (2.9); statin, 16.3 (3.0); pravastatin, 16.2 (3.2); simvastatin, 16.5 (2.8). Pravastatin differed significantly from placebo (P = .007) and nonsignificantly from simvastatin (P = .09).

^bP values are for t test of difference in mean for designated statin vs placebo.

^cResults of ordinal logistic regression, with robust standard errors, adjusted for baseline EnergyFatigEx: statin, β (SE), −0.51 (0.13) (P < .001); simvastatin, β (SE), −0.68 (0.15) (P < .001); and pravastatin, β (SE), −0.33 (0.15) (P = .03).